Similarly, USP22 was also shown to promote hepatocellular cancer cell chemotherapy resistance, nasopharyngeal carcinoma progression, and gastric cancer tumorigenic properties by stimulating the PI3K/AKT- and the MAPK-signaling [44–46]. The gene discussed is USP22; the disease is hepatocellular carcinoma.